La catena delle opzioni mostra i dati chiave delle opzioni azionarie di HeartBeam a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per HeartBeam..

HeartBeam (NASDAQ:BEAT) Azioni, Catena delle Opzioni

HeartBeam

HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

HeartBeam Inc

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54277068&amp;newsitemid=20250617270939&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=b6dfd00834f3e12c6b934a69954d0400">HeartBeam, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer, will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Eno and Cruickshank will also host virtual one-on-one meetings with institutional investors during the event.
iAccess Alpha Virtual Summer Conference Dates: June 24-25, 2025 Location: Virtual Format: Presentation and Virtual 1x1 Meetings Attendees: Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer Presentation Time: 2:00 p.m. Eastern Time on June 24 Webcast: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.webcaster4.com%2FWebcast%2FPage%2F3118%2F52509&amp;esheet=54277068&amp;newsitemid=20250617270939&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.webcaster4.com%2FWebcast%2FPage%2F3118%2F52509&amp;index=2&amp;md5=699062b2a9fa4b3694ae594aa4367234">https://www.webcaster4.com/Webcast/Page/3118/52509</a>
A webcast of the presentation will also be available under the Events section of the Company's investor relations website linked <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.heartbeam.com%2F&amp;esheet=54277068&amp;newsitemid=20250617270939&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=6fe182e043861732ab79a99468bbef56">here</a>.
To schedule a one-on-one investor meeting with HeartBeam management, please contact your iAccess Alpha conference representative or email your request to <a href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> or call Chris Tyson at (949) 491-8235.

News

BEAT

HeartBeam to Share Cardiac Tech Vision With Investors at iAccess Alpha Summer Conference

<h3>Gainers</h3>
<ul>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares rose 37.5% to $9.21 during Monday's pre-market session. The company's market cap stands at $576.7 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares increased by 37.43% to $0.03. The company's market cap stands at $11.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 20.58% to $0.39. The company's market cap stands at $11.8 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares increased by 17.21% to $5.48. The market value of their outstanding shares is at $2.8 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares rose 15.89% to $1.75. The market value of their outstanding shares is at $59.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares rose 15.49% to $0.13. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock decreased by 39.8% to $21.79 during Monday's pre-market session. The market value of their outstanding shares is at $2.1 billion. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) stock decreased by 11.51% to $1.0. The market value of their outstanding shares is at $33.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 11.21% to $0.32. The company's market cap stands at $4.0 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock declined by 9.36% to $0.25. The company's market cap stands at $8.4 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock declined by 7.69% to $1.32. The market value of their outstanding shares is at $23.1 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock fell 7.39% to $0.61. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APDN

BFRI

CODX

HCTI

IMNN

JUNS

NCNA

ONMD

SAGE

SRPT

VTAK

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock rose 45.4% to $0.39 during Wednesday's pre-market session. The company's market cap stands at $57.7 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares moved upwards by 42.5% to $0.18. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock moved upwards by 33.67% to $20.35. The company's market cap stands at $122.5 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) shares moved upwards by 22.64% to $1.3. The company's market cap stands at $64.8 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares moved upwards by 19.23% to $0.01. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock moved upwards by 12.11% to $1.8. The market value of their outstanding shares is at $10.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares declined by 12.7% to $1.9 during Wednesday's pre-market session. The company's market cap stands at $9.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) stock declined by 11.75% to $1.45. The company's market cap stands at $121.1 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 9.16% to $6.25. The company's market cap stands at $3.6 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares decreased by 9.06% to $3.0. The market value of their outstanding shares is at $417.1 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares fell 9.04% to $1.51. The market value of their outstanding shares is at $51.0 million. </li>
<li>Akso Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares declined by 8.13% to $1.52. The company's market cap stands at $606.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

BDSX

EDIT

IMRN

KDLY

PLRZ

PTIX

PTPI

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year.

Earnings

Earnings Misses

HeartBeam Q1 EPS $(0.18) Misses $(0.15) Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

HeartBeam Announced The Addition Of Two New U.S. Patents, Reinforcing Its Core Intellectual Property Position And Enabling Future Product Extensions

<ul>
<li>First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the defensive and offensive moat around the company's core technology</li>
<li>Second patent expands the use of risk-based diagnostic algorithms into HeartBeam's product portfolio around wearable devices</li>
<li>HeartBeam now has 20 issued patents worldwide, cementing Company's leadership in cardiac monitoring innovation</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54249202&amp;newsitemid=20250506303008&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=ad0e0f6a02ff4a461ad100d46e36c059">HeartBeam, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling future product extensions. The patents reinforce HeartBeam's groundbreaking innovations and further solidify the Company's intellectual property (IP) footprint in cardiac monitoring technology that bring advanced cardiac insights to patients and clinicians.
The first patent protects IP around HeartBeam's credit card-sized, cable-free 3D ECG device. Designed for ease of use, the device features chest and finger electrodes to capture high-fidelity electrical signals in 3D (by capturing 3 non-coplanar directions) – enabling patients to record their symptoms the moment they occur, wherever they are. The signals are then synthesized into a familiar 12-lead ECG using a personalized transformational matrix. The 12-lead ECG synthesis software is currently under review with the FDA. <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.heartbeam.com%2Fnews-events%2Fpress-releases%2Fdetail%2F92%2Fheartbeam-successfully-meets-clinical-endpoints-in-pivotal&amp;esheet=54249202&amp;newsitemid=20250506303008&amp;lan=en-US&amp;anchor=Data+from+the+VALID-ECG+pivotal+study&amp;index=2&amp;md5=7ef3c476ceaaffb653e88c996c591cc0">Data from the VALID-ECG pivotal study</a> supporting the FDA submission was presented at the Heart Rhythm Society conference in April 2025.
The second patent protects HeartBeam's rhythm analysis algorithm, which distinguishes between sinus rhythm, atrial fibrillation, and other arrhythmias using continuous signal input. Designed to operate on any cardiac monitoring system including wearables, the algorithm enables risk-based escalation by detecting anomalies during passive monitoring and prompting the user to collect high-fidelity 3D ECG signals with HeartBeam's credit card-sized device, enabling synthesis of a 12-lead ECG.
"HeartBeam's vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility. The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care," said Robert Eno, Chief Executive Officer of HeartBeam.
With these two new U.S. patents, HeartBeam now holds 20 issued US and international patents, as well as 2 allowed patents and 32 pending patents, adding to an already robust IP portfolio that supports the company's differentiated position in remote cardiac diagnostics. These innovations lay the groundwork for future capabilities such as AI-driven classification algorithms and ischemia detection, further extending HeartBeam's potential to provide unprecedented cardiac insights to individuals and physicians.

HeartBeam Announces It Has Received Two New U.S. Patents

Milestone results formed the basis of HeartBeam's 12-lead ECG synthesis software application submitted to FDA in January 2025
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54245378&amp;newsitemid=20250429345605&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=c672ecafee146a571f5da284ab5c541e">HeartBeam, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that its groundbreaking synthesized 12-lead electrocardiogram (ECG) successfully met the clinical endpoints in the VALID-ECG pivotal study. Thomas Deering, M.D., of Piedmont Heart Institute, presented the data during the just concluded Heart Rhythm Society's annual conference in San Diego.
The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam's synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing non-life-threatening arrhythmias. Data showed a 93.4% overall diagnostic agreement, indicating that HeartBeam's synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs.

HeartBeam's Synthesized 12-lead Electrocardiogram Meets Clinical Endpoints In VALID-ECG Pivotal Study

Collaboration brings together two leaders in ambulatory ECG recording and analysis
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54242849&amp;newsitemid=20250424671250&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=301e7944ad32d33f512431db602073d0">HeartBeam, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a strategic collaboration with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.accurkardia.com%2F&amp;esheet=54242849&amp;newsitemid=20250424671250&amp;lan=en-US&amp;anchor=AccurKardia&amp;index=2&amp;md5=f123a1fb0bbd1ac7b2b6b3ce3c18b3cc">AccurKardia</a>, an innovator in ECG-based diagnostics technology, bringing together two innovation leaders in ambulatory electrocardiogram (ECG) recording and analysis. The initial collaboration aims to enhance the accessibility of cardiac monitoring solutions and will focus on making AccurKardia's FDA-cleared ECG analysis software, AccurECG&#x2122;, available on HeartBeam's devices.&#x2A;
"This collaboration is a major step forward in delivering a more accessible and scalable solution for remote cardiac monitoring," said Robert Eno, Chief Executive Officer of HeartBeam. "AccurKardia shares our mission of improving cardiac outcomes through technological innovation, and together we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of a medical facility."

Biotech

Contracts

General

HeartBeam And AccurKardia Enters Strategic Collaboration To Advance Cardiac Monitoring Innovation

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.19) by 284.21 percent.

HeartBeam Q4 2024 Adj EPS $(0.73) Misses $(0.19) Estimate

<h3>Companies Reporting Before The Bell</h3>
• Advanced Flower Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $11.76 million. 
• Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) is likely to report quarterly loss at $0.13 per share on revenue of $28.55 million. 
• Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $15.80 million. 
• ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) is expected to report quarterly loss at $0.09 per share on revenue of $9.61 million. 
• CION Invt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CION#NYSE">CION</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $54.11 million. 
• Altisource Portfolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>) is expected to report earnings for its fourth quarter. 
• US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $4.54 million. 
• Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $37.36 million. 
• G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is likely to report quarterly earnings at $0.97 per share on revenue of $807.11 million. 
• Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report earnings for its fourth quarter. 
• Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) is projected to report quarterly loss at $0.16 per share on revenue of $13.39 million. 
• Global X Guru Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GURU#NYSE">GURU</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $8.67 million. 
• D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $2.23 million. 
• Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) is projected to report quarterly loss at $0.02 per share on revenue of $81.68 million. 
• Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $204.70 million. 
• CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $27.99 million. 
• Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $50.53 million. 
• Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is expected to report quarterly earnings at $1.50 per share on revenue of $10.26 billion. 
• Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) is estimated to report quarterly earnings at $1.50 per share on revenue of $147.53 million. 
• Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is estimated to report earnings for its fourth quarter. 
• Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $499.61 million. 
• Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is projected to report quarterly loss at $0.49 per share on revenue of $142.21 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $25.15 million. 
• Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is projected to report earnings for its fourth quarter. 
• Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is expected to report earnings for its fourth quarter. 
• Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $76.67 million. 
• Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is likely to report quarterly loss at $0.47 per share on revenue of $2.67 million. 
• Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) is likely to report earnings for its fourth quarter. 
• Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) is estimated to report earnings for its fourth quarter. 
• Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) is likely to report quarterly loss at $0.07 per share on revenue of $47.75 million. 
• Duluth Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) is estimated to report quarterly earnings at $0.11 per share on revenue of $252.86 million. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $451.76 million. 
• Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $42.80 million. 
<h3>Companies Reporting After The Bell</h3>
• Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $394.49 million. 
• DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $761.31 million. 
• Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.08 per share on revenue of $130.60 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is likely to report quarterly earnings at $1.82 per share on revenue of $1.63 billion. 
• Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) is expected to report earnings for its third quarter. 
• Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is likely to report quarterly loss at $0.35 per share on revenue of $118.90 million. 
• Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.10 per share on revenue of $10.37 million. 
• Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) is projected to report quarterly loss at $0.21 per share on revenue of $9.09 million. 
• Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is expected to report earnings for its fourth quarter. 
• Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) is estimated to report quarterly earnings at $0.77 per share on revenue of $253.99 million. 
• Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) is expected to report earnings for its fourth quarter. 
• Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) is likely to report quarterly loss at $0.63 per share on revenue of $3.08 million. 
• Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $161.36 million. 
• FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is expected to report quarterly loss at $0.04 per share on revenue of $29.02 million. 
• aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) is projected to report earnings for its fourth quarter. 
• Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $142.61 million. 
• PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) is projected to report quarterly loss at $0.42 per share on revenue of $7.70 million. 
• VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $108.91 million. 
• Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) is expected to report quarterly loss at $0.18 per share on revenue of $12 thousand. 
• Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $2.77 million. 
• WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $46.00 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $250.17 million. 
• Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $276.46 million. 
• OPAL Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPAL#NASDAQ">OPAL</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $92.09 million. 
• Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is expected to report quarterly loss at $0.14 per share on revenue of $30.77 million. 
• HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) is estimated to report earnings for its fourth quarter. 
• Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $102.27 million. 
• AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) is expected to report earnings for its fourth quarter. 
• PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is likely to report quarterly loss at $0.11 per share on revenue of $14.30 million. 
• Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) is projected to report quarterly loss at $1.11 per share on revenue of $23.52 million. 
• Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $22.29 million. 
• Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $81.42 million. 
• ZOMEDICA CORP COM (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#AMEX">ZOM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $8.10 million. 
• GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) is projected to report quarterly loss at $0.11 per share on revenue of $42.21 million. 
• Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $40.13 million. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $119.53 million. 
• EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $170.48 million. 
• Drilling Tools Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTI#NASDAQ">DTI</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $36.08 million. 
• AlTi Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $74.60 million. 
• Origin Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $9.08 million. 
• Heritage Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $12.30 million. 
• Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is likely to report quarterly loss at $0.39 per share on revenue of $232.91 million. 
• Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $348.33 million. 
• ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) is projected to report earnings for its first quarter. 
• Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) is estimated to report quarterly earnings at $7.13 per share on revenue of $3.47 billion. 
• Portman Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTMN#NASDAQ">PTMN</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.33 million. 
• Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $5.00 million. 
• Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $28.95 million. 
• BuzzFeed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZFD#NASDAQ">BZFD</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACTG

AFCG

AGRO

AKBA

ALTI

APYX

ASPS

ATYR

AVAH

BAER

BLDE

BLDP

BLNK

BZFD

CCLD

CION

CLLS

CNTY

DLTH

DOCU

EVCM

EVOK

FEIM

FUTU

GIII

GRWG

GURU

HGBL

JYNT

LCUT

LRFC

MAPS

MCRB

NOTE

NYXH

OPAL

ORGN

PANL

PESI

PHAR

PLBY

PRPL

PSQH

PTMN

QBTS

QNRX

RBRK

RGNX

SHIM

SKLZ

SMTC

SOHO

TACT

TBCH

TTAN

ULTA

USEG

VERI

VUZI

XNET

XPOF

ZSPC

ZUMZ

Earnings Scheduled For March 13, 2025

Offerings

HeartBeam Prices $10.0M Underwritten Public Offering Of  5,882,353 Shares At $1.70/Share

Heartbeam Has Submitted A 510(K) Application To The U.S. Food And Drug Administration For The Company's  12-Lead Electrocardiogram Synthesis Software Designed For The Assessment Of Rhythms And Arrhythmias

Heartbeam Filed For Common Stock Offering Of Up To $10M

WIIM

Heartbeam shares are trading lower amid a possible selloff. The stock initially traded higher after the company announced FDA clearance for its HeartBeam system, but it has since reversed.

HeartBeam shares are trading higher after the FDA granted the company 510(k) clearance of its system for comprehensive arrhythmia assessment.

HeartBeam Announced FDA Clearance For Its HeartBeam System For Comprehensive Arrhythmia Assessment

HeartBeam Unveils Data At AHA 2024 For Portable Credit Card-Sized ECG Device; Studies Demonstrate Comparable Arrhythmia Detection To Standard ECGs And Highlight Remote Chest Pain Evaluation To Reduce Heart Attack Care Delays

Comments

HeartBeam

HeartBeam (BEAT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO